scholarly journals LAPORAN KASUS: PERDARAHAN INTRASEREBRAL PADA ACQUIRED PROTHROMBIN COMPLEX DEFICIENCY ONSET LAMBAT

2018 ◽  
Vol 1 (2) ◽  
Author(s):  
Clarissa Tertia ◽  
Kennytha Yoesdyanto ◽  
Imam Irfani ◽  
Herliana Sembiring
Keyword(s):  
Vitamin K ◽  
Partial Thromboplastin Time ◽  
Activated Partial Thromboplastin Time ◽  
Fluid Level ◽  
Complex Deficiency

Latar Belakang: Acquired Prothrombin Complex Deficiency (APCD) adalah pendarahan akibat kekurangan vitamin K. Manifestasi klinis berupa defisit neurologis fokal maupun global yang berhubungan dengan perdarahan intraserebral spontan. Kasus: Bayi laki-laki 1 bulan mengalami penurunan kesadaran, bangkitan, serta muntah sejak 1 hari sebelumnya. Riwayat injeksi vitamin K dan trauma kepala disangkal. Bayi somnolen, pucat, ubun-ubun menonjol, pupil anisokoria, dan ekstremitas spastik. Pemeriksaan laboratorium menunjukkan trombositosis, pemanjangan partial thromboplastin time (PT) dan activated partial thromboplastin time (APTT). CT sken menunjukkan perdarahan intraserebral multipel, subarakhnoid, dan subdural, iskemia luas, dan fluid-fluid level. Pasien diterapi dengan asam traneksamat, vitamin K, antikonvulsan, dan dirujuk ke RS dengan fasilitas layanan bedah saraf. Diskusi: Diagnosis APCD ditegakkan berdasarkan pemanjangan protrombin dan perdarahan spontan yang ditunjang oleh CT sken kepala. Simpulan: Kasus APCD memiliki tingkat morbiditas dan mortalitas yang tinggi sehingga profilaksis vitamin K pada neonatus sangat penting.

Maternal Administration of Vitamin K Does Not Improve the Coagulation Profile of Preterm Infants

PEDIATRICS ◽  
1989 ◽  
Vol 84 (6) ◽  
pp. 1045-1050
Author(s):  
Nadya J. Kazzi ◽  
Nestor B. Ilagan ◽  
Keh-Chyang Liang ◽  
George M. Kazzi ◽  
Ronald L. Poland ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Prothrombin Time ◽  
Vitamin K ◽  
Partial Thromboplastin Time ◽  
Intraventricular Hemorrhage ◽  
Time Factors ◽  
Activated Partial Thromboplastin Time ◽  
Vitamin K1 ◽  
Time Activity ◽  
Maternal Administration

The effect of maternal administration of vitamin K1 on cord blood prothrombin time, activated partial thromboplastin time, activity of factors II, VII, and X, and antigen levels of factors II and X in infants < 35 weeks' gestation was evaluated. Pregnant women in preterm labor were randomly assigned to receive 10 mg of vitamin K1 intramuscularly or no injection. If delivery did not occur in 4 days, the dose of vitamin K1 was repeated. Women who continued their pregnancy 4 days beyond the second dose received 20 mg of vitamin K1 orally daily until the end of the 34th week of gestation. The birth weights of infants ranged from 370 to 2550 g and gestational age ranged from 22 to 34 weeks. The prothrombin time, activated partial thromboplastin time, factors II, VII, and X activity, and factors II and X antigen levels were not statistically different in either group of infants. Intraventricular hemorrhage occurred in 25 of 51 control infants and 25 of 47 vitamin K-treated infants. More control infants had grade III intraventricular hemorrhage on day 1 (P = .032), but on day 3 and 14 of life, the severity of intraventricular hemorrhage was comparable in both groups. Infants in whom an intraventricular hemorrhage developed were significantly smaller, younger, and more critically ill than infants without intraventricular hemorrhage. Administration of vitamin K1 to pregnant women at < 35 weeks' gestation does not improve the hemostatic defects nor does it reduce the incidence or severity of intraventricular hemorrhage in their infants.

Haemorrhage in seven cats with suspected anticoagulant rodenticide intoxication

2003 ◽  
Vol 5 (5) ◽  
pp. 295-304 ◽  
Author(s):  
B Kohn ◽  
C Weingart ◽  
U Giger
Keyword(s):  
Body Weight ◽  
Blood Plasma ◽  
Vitamin K ◽  
Whole Blood ◽  
Partial Thromboplastin Time ◽  
Reference Range ◽  
Activated Partial Thromboplastin Time ◽  
Anticoagulant Rodenticide ◽  
Plasma Coagulation ◽  
Adult Cats

Clinical features were evaluated in seven adult cats (six males, one female) with haemorrhage and presumptive anticoagulant rodenticide intoxication. Haemorrhage appeared as thoracic haemorrhage, otic bleeding, haematoma, melena, haematochezia, and petechiation. The most common other presenting signs were lethargy, anorexia, and tachypnoea or dyspnoea. Six cats were anaemic, four cats were mildly thrombocytopenic (58 000–161 000/μl), and three had slightly decreased plasma protein or albumin values. The prothrombin time (30.3–>100 s, reference range: 16.5–27.5 s) and activated partial thromboplastin time values (32.6–>100 s; reference range: 14–25 s) were markedly prolonged in all cats. All cats received vitamin K1 subcutaneously or orally (3.7–5 mg/kg body weight initially) and depending on severity of signs five cats were transfused with fresh whole blood. Plasma coagulation times improved in all cats and returned to normal in 1–5 days. Rodenticide poisons represent an important but relatively rare cause of haemorrhage in cats and can be effectively treated.

scholarly journals Effect of oral vitamin K prophylaxis on prothrombine time and activated partial thromboplastin time: a randomized controlled comparison with an intramuscular vitamin K in infants

2007 ◽  
Vol 47 (3) ◽  
pp. 109
Author(s):  
V. Lily Limantara ◽  
Sudaryat S. ◽  
I. B. Mudita ◽  
W. Retayasa ◽  
M. Kardana
Keyword(s):  
Vitamin K ◽  
Partial Thromboplastin Time ◽  
Neonatal Period ◽  
Newborn Infants ◽  
Activated Partial Thromboplastin Time ◽  
P Value ◽  
Oral Vitamin ◽  
Randomized Controlled ◽  
Hemorrhagic Event ◽  
Oral Group

Background Low plasma concentration of vitamin K in thenewborn accounts for serious bleeding in the neonatal period andearly infancy. The aim of prophylactic vitamin K is to preventbleeding. Oral prophylaxis is preferable to intramuscular (IM)administration because oral administration is less expensive andless traumatic.Objective To compare oral vs. intramuscular vitamin K onprothrombine time (PT) and activated partial thromboplastin time(APTT) during the first 60 days of life.Methods We randomized newborn infants to either receive oralvitamin K 2 mg at birth and repeated at 7 and 30 days of life orthe 1 mg intramuscular vitamin K. PT and APTT were monitoredat 0, 15, and 45 days of age. Independent t-test, repeatedmeasurement, and regression analysis were used for statisticalanalyses and comparison of the results.Results Fifty infants were assigned into the oral group and 50 tothe IM group. All participants completed 60 days of study. BothPT and APTT decreased after administration of oral or IM vitaminK, and the values did not differ significantly at any time pointand through the period of investigation. Using regression analysisit was shown that only vitamin K administration was correlatedwith PT and APTT with P value were 0.044 and 0.036,respectively. During 60 days of study, there was no hemorrhagicdiathesis in both groups.Conclusions Through the first 60 days of life, 3 doses of oralvitamin K maintain hemostasis by decreasing PT and APTT ininfants at values equal to those achieved by the intramuscularpreparation. Diathesis hemorrhagic event did not occur in bothgroups.

scholarly journals THE RISKS OF USING TRANEXAMIC ACID AND VITAMIN K FOR DECREASING PROTHROMBIN TIME AND ACTIVATED PARTIAL THROMBOPLASTIN TIME VALUES IN INTRACRANIAL HEMORRHAGIC PATIENTS AT RUMAH SAKIT UMUM PUSAT FATMAWATI JAKARTA

2017 ◽  
Vol 10 (17) ◽  
pp. 139
Author(s):  
Siti Zamilatul Azkiyah ◽  
Sudibyo Supardi ◽  
Retnosari Andrajati
Keyword(s):  
Statistical Analysis ◽  
Tranexamic Acid ◽  
Prothrombin Time ◽  
Vitamin K ◽  
Partial Thromboplastin Time ◽  
Medical Records ◽  
Vascular Malformations ◽  
Activated Partial Thromboplastin Time ◽  
Chi Squared ◽  
Threatening Condition

Objective: Intracranial hemorrhaging is a life-threatening condition that requires intensive treatment. Such hemorrhaging can happen spontaneously and may be caused by vascular malformations, trauma, or the administration of anticoagulant medications. The purpose of this study was to evaluate the risks of using tranexamic acid and Vitamin K for decreasing prothrombin time (PT) and activated partial thromboplastin time (aPTT) values in intracranial hemorrhagic patients.Methods: This study used a retrospective cohort design, and data were taken from patients’ medical records at the medical record installation of Rumah Sakit Umum Pusat Fatmawati in Jakarta. A total of 125 medical records were selected based on the inclusion criteria. The first group included patients receiving only tranexamic acid, and the second group consisted of patients receiving both tranexamic acid and Vitamin K.Results: Statistical analysis using Chi-squared testing for the first group showed a significant decrease in aPTT values, with p=0.000 (p<0.05), but there was no significant decrease in PT values, with p=0.314 (p<0.05). Statistical analysis using Chi-squared testing in the second group showed a significant decrease in aPTT values, with p=0.000 (p<0.05), and a significant decrease in PT values, with p=0.034 (p<0.05). Patients that used tranexamic acid and Vitamin K decreased the PT and aPTT values 2.7 times and 1, 6 times greater than patients without tranexamic acid and Vitamin K. Patients that used tranexamic acid decreased the PT and aPTT values 2.5 times and 1.2 times greater than patients without tranexamic acid.Conclusions: The combination of tranexamic acid and Vitamin K is potentially more effective in decreasing of hemorrhaging.

scholarly journals INTRACEREBRAL BLEEDING IN LATE HEMORRHAGIC DISEASE OF THE NEWBORN

2019 ◽  
pp. 1-2
Author(s):  
Jayashree Nadkarni
Keyword(s):  
Platelet Count ◽  
Prothrombin Time ◽  
Vitamin K ◽  
Partial Thromboplastin Time ◽  
Late Onset ◽  
Activated Partial Thromboplastin Time ◽  
The Body ◽  
Hemorrhagic Disease ◽  
Normal Platelet Count ◽  
Normal Platelet

Late onset HDN can present as bleeding from any site of the body but more commonly from intracranial vessels. It is diagnosed if bleeding occurs after 7th day of life with normal platelet count, prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT), associated with stopping of bleeding and PT/PTTreturning to normal after giving vitamin K. Among the types of intracranial bleeding in late hemorrhagic disease of newborn, intracerebral parenchymal bleeding is least common.

Monitoring Heparin Therapy: Relationships between the Activated Partial Thromboplastin Time and Heparin Assays Based on Ex-Vivo Heparin Samples

1990 ◽  
Vol 63 (01) ◽  
pp. 016-023 ◽  
Author(s):  
A M H P van den Bessekaar ◽  
J Meeuwisse-Braun ◽  
R M Bertina
Keyword(s):  
Partial Thromboplastin Time ◽  
Plasma Sample ◽  
Ex Vivo ◽  
Correlation Coefficients ◽  
Heparin Therapy ◽  
Thromboembolic Disease ◽  
Activated Partial Thromboplastin Time ◽  
Venous Thromboembolic Disease ◽  
Venous Thromboembolic

SummaryFive different APTT reagents, two amidolytic anti-ITa assays, one amidoiytic anti-Xa assay, and one coagulometric anti-Xa/ anti-IIa assay were used to assess the effect of heparin in patients treated for venous thromboembolic disease. Good correlations were observed between lug-transformed APYE> determined with the various reagents (correlation coefficients: 0.92-0.96).Nevertheless there were important differences in the slopes of the lines of relationship between the APTT reagents.Good correlations were observed between the anti-Xa and anti-IIa assay results (correlation coefficients: 0.92-0.97). However, the amidolytic anti-Xa activity was significantly higher (p <0.001) than the two amidolytic anti-IIa activities. Less good correlations were observed between the log-transformed APTTs and the anti-Xa or anti-IIa activities (correlation coefficients: 0.64-0.78). The correlations were improved by transforming the APTT into APTT-ratio, i.e. the ratio of the patient’s APTT to the same patient’s APTT after removal of heparin from the plasma sample by means of ECTEOLA-cellulose treatment. The correlation coefficients of log (AFTT-ratio) with anti-Xa or anti-IIa ranged from 0.76 to 0.87.For both APTT and amidolytic heparin assay, the response to in vitro heparin was different from the response to ex vivo heparin.Therefore, equivalent therapeutic ranges should be assessed by using ex vivo samples rather than in vitro heparin. Because of the response differences between the APTT reagents, it is not adequate to define a therapeutic range for heparin therapy without specification of the reagent.

Sign in / Sign up

Export Citation Format

Share Document